Expanding the universe of new treatments for patients

Arrakis Therapeutics Announces Presentations at Upcoming Fall Scientific Meetings

Waltham, Mass., September 25, 2023 – Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that the company will participate in three upcoming scientific meetings. The presentations will describe continuing R&D advancements by Arrakis as the company discovers RNA-targeted medicines for therapeutic applications, including cancer and other diseases.

Details of the Arrakis presentations are as follows: 

Discovery on Target: Small Molecules Targeting RNA, Boston, MA
Presentation Title: Structure-based Design of Small Molecule Inhibitors of RNA
Date: Tuesday, September 26
Time: 1:20 p.m. ET
Presenter: Jennifer Petter, PhD, Founder & Chief Innovation Officer

Discovery US 2023, Cambridge, MA
Presentation Title: In Silico Discovery of Group II Intron RNA Splicing Inhibitors
Date: Thursday, November 2
Presenter: Aaron Frank, PhD, Director, Computational Chemistry

Presentation Title: A Data-driven Approach to Discovering RNA-targeted Small Molecules
Date: Thursday, November 2
Presenter: David Mauger, PhD, Director, Data Sciences

6th RNA Targeted Drug Discovery & Development Summit
Presentation Title: Examining the Intricacies of the Small Molecule Landscape to Influence Future Direction of RNA-Targeted Drug Discovery
Date: Wednesday, December 13
Time: 4:30 p.m. ET
Presenter: Jennifer Petter, PhD, Founder & Chief Innovation Officer

About Arrakis Therapeutics
Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors. The company is located in Waltham, Massachusetts. For more information, please visit www.arrakistx.com and engage with us on Twitter @ArrakisTx or on LinkedIn.